Verve Therapeutics vs Insilico Medicine

Side-by-side comparison of AI visibility scores, market position, and capabilities

Insilico Medicine leads in AI visibility (43 vs 20)
Verve Therapeutics logo

Verve Therapeutics

EmergingBiotechnology

Cardiovascular Gene Editing

Verve Therapeutics develops single-course gene editing medicines for cardiovascular disease, aiming to permanently lower LDL cholesterol with one treatment.

AI VisibilityBeta
Overall Score
D20
Category Rank
#1 of 1
AI Consensus
67%
Trend
up
Per Platform
ChatGPT
19
Perplexity
19
Gemini
26

About

Verve Therapeutics is a clinical-stage genetic medicines company founded in 2018 by Andrew Bellinger and Sekar Kathiresan, focused exclusively on using base editing to treat cardiovascular disease. The company is developing one-time treatments that permanently lower LDL cholesterol and triglycerides by editing genes in liver cells that regulate lipid metabolism, including PCSK9 and ANGPTL3. Verve's approach targets the root cause of common cardiovascular disease rather than requiring lifelong daily medication, with the goal of a single infusion delivering durable benefit. The lead program VERVE-101 targets PCSK9 in liver cells and has entered Phase 1b clinical trials, with early data showing substantial and durable LDL reductions in patients with heterozygous familial hypercholesterolemia. Verve is publicly traded on Nasdaq and has established partnerships with Vertex Pharmaceuticals to advance the cardiovascular base editing pipeline. The company represents a fundamentally new approach to preventing heart attacks and strokes at the genetic level.

Full profile
Insilico Medicine logo

Insilico Medicine

ChallengerLife Sciences & BioTech

Drug Discovery & Development

Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.

AI VisibilityBeta
Overall Score
C43
Category Rank
#1 of 1
AI Consensus
66%
Trend
up
Per Platform
ChatGPT
39
Perplexity
46
Gemini
38

About

Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.

Full profile

AI Visibility Head-to-Head

20
Overall Score
43
#1
Category Rank
#1
67
AI Consensus
66
up
Trend
up
19
ChatGPT
39
19
Perplexity
46
26
Gemini
38
19
Claude
48
31
Grok
35

Key Details

Category
Cardiovascular Gene Editing
Drug Discovery & Development
Tier
Emerging
Challenger
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Verve Therapeutics
Cardiovascular Gene Editing
Only Insilico Medicine
Drug Discovery & Development
Insilico Medicine is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.